GlaxoSmithKline Pharmaceuticals Share Price
Start SIP in GlaxoSmithKline Pharmaceuticals
Start SIPGlaxoSmithKline Pharmaceuticals Performance
Day Range
- Low 2,741
- High 2,845
52 Week Range
- Low 1,385
- High 3,088
- Open Price2,845
- Previous Close2,829
- Volume67698
Glaxosmithkline Pharmaceuticals Investment Rating
-
Master Rating:
-
Glaxosmithkline Pharms. has an operating revenue of Rs. 3,506.70 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 24% is great, ROE of 33% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 26% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 93 which is a GREAT score indicating consistency in earnings, a RS Rating of 68 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 46 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 811 | 911 | 805 | 953 | 738 | 782 |
Operating Expenses Qtr Cr | 582 | 656 | 587 | 667 | 597 | 615 |
Operating Profit Qtr Cr | 229 | 255 | 218 | 287 | 141 | 167 |
Depreciation Qtr Cr | 16 | 18 | 17 | 18 | 16 | 17 |
Interest Qtr Cr | 0 | 1 | 0 | 0 | 0 | 1 |
Tax Qtr Cr | 67 | 76 | 20 | 81 | 48 | 56 |
Net Profit Qtr Cr | 182 | 193 | 45 | 216 | 131 | 131 |
GlaxoSmithKline Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 7
- Bearish Moving Average
- ___
- 9
- 20 Day
- ₹2,836.38
- 50 Day
- ₹2,763.47
- 100 Day
- ₹2,602.56
- 200 Day
- ₹2,341.60
- 20 Day
- ₹2,852.66
- 50 Day
- ₹2,772.09
- 100 Day
- ₹2,581.10
- 200 Day
- ₹2,304.66
GlaxoSmithKline Pharmaceuticals Resistance and Support
Resistance | |
---|---|
First Resistance | 2,848.90 |
Second Resistance | 2,898.90 |
Third Resistance | 2,952.80 |
RSI | 47.43 |
MFI | 53.46 |
MACD Single Line | 19.93 |
MACD | 12.33 |
Support | |
---|---|
First Support | 2,745.00 |
Second Support | 2,691.10 |
Third Supoort | 2,641.10 |
GlaxoSmithKline Pharmaceuticals Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 71,872 | 3,870,307 | 53.85 |
Week | 71,889 | 3,826,662 | 53.23 |
1 Month | 115,747 | 5,699,371 | 49.24 |
6 Month | 172,666 | 8,338,057 | 48.29 |
GlaxoSmithKline Pharmaceuticals Result Highlights
GlaxoSmithKline Pharmaceuticals Synopsis
NSE-Medical-Diversified
Glaxosmithkline Phar is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3407.25 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2024. GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151.Market Cap | 47,923 |
Sales | 3,480 |
Shares in Float | 4.24 |
No of funds | 303 |
Yield | 1.13 |
Book Value | 26.86 |
U/D Vol ratio | 2.3 |
LTDebt / Equity | |
Alpha | 0.17 |
Beta | 0.69 |
GlaxoSmithKline Pharmaceuticals Shareholding Pattern
Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
---|---|---|---|---|
Promoters | 75% | 75% | 75% | 75% |
Mutual Funds | 4.71% | 4.51% | 4.5% | 4.81% |
Insurance Companies | 2.67% | 3.25% | 4.02% | 5.15% |
Foreign Portfolio Investors | 4.02% | 3.48% | 2.93% | 2.5% |
Financial Institutions/ Banks | 0.01% | 0.01% | 0.01% | 0.01% |
Individual Investors | 11.15% | 11.27% | 11.08% | 10.62% |
Others | 2.44% | 2.48% | 2.46% | 1.91% |
GlaxoSmithKline Pharmaceuticals Management
Name | Designation |
---|---|
Ms. R S Karnad | Chairperson |
Mr. B Akshikar | Managing Director |
Mr. J Chandy | WholeTime Director & CFO |
Mr. S Williams | Non Executive Director |
Mr. M Anand | Independent Director |
Dr.(Ms.) S Maheshwari | Independent Director |
Mr. A N Roy | Independent Director |
Mr. D Sundaram | Independent Director |
Mr. P V Bhide | Independent Director |
GlaxoSmithKline Pharmaceuticals Forecast
Price Estimates
GlaxoSmithKline Pharmaceuticals Corporate Action
Date | Purpose | Remarks |
---|---|---|
2024-08-02 | Quarterly Results | |
2024-05-17 | Audited Results & Final Dividend | |
2024-02-12 | Quarterly Results | |
2023-11-09 | Quarterly Results | |
2023-07-26 | Quarterly Results |
Date | Purpose | Remarks |
---|---|---|
2024-05-31 | FINAL | Rs.32.00 per share(320%)Final Dividend |
2023-06-30 | FINAL | Rs.32.00 per share(320%)Final Dividend |
2022-07-08 | FINAL | Rs.30.00 per share(300%)Dividend |
2022-07-08 | SPECIAL | Rs.60.00 per share(600%)Special Dividend |
2021-07-20 | FINAL | Rs.30.00 per share(300%)Dividend |
GlaxoSmithKline Pharmaceuticals FAQs
What is Share Price of GlaxoSmithKline Pharmaceuticals ?
GlaxoSmithKline Pharmaceuticals share price is ₹2,798 As on 18 September, 2024 | 02:23
What is the Market Cap of GlaxoSmithKline Pharmaceuticals ?
The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹47415 Cr As on 18 September, 2024 | 02:23
What is the P/E ratio of GlaxoSmithKline Pharmaceuticals ?
The P/E ratio of GlaxoSmithKline Pharmaceuticals is 74.1 As on 18 September, 2024 | 02:23
What is the PB ratio of GlaxoSmithKline Pharmaceuticals ?
The PB ratio of GlaxoSmithKline Pharmaceuticals is 26.7 As on 18 September, 2024 | 02:23